Market Overview

UPDATE: Bank of America Raises PT on C.R. Bard Following CEO/CFO Meetings

Related BCR
Bard Agrees to Acquire Full Ownership of its Joint Venture in Japan
Benzinga's Top Upgrades
C.R. Bard Gains Full Ownership of Medicon, Expands in Japan (Zacks)

In a report published Thursday, Bank of America analyst Bob Hopkins reiterated a Buy rating on C.R. Bard (NYSE: BCR), and raised the price target from $125.00 to $140.00.

In the report, Bank of America noted, “We are raising our PO for BCR to $140 today after our recent meetings with BCR's CEO and CFO. Our higher PO is based on our increased confidence in BCR's financial outlook. BCR remains broadly out of favor, but we see a clear pathway to accelerating growth and upside to numbers and we view the risk reward on near term catalysts as very favorable. BCR trades at 11.8x our view of BCR's potential 2015 cash earnings power and the average medtech company trades at about 12.3x 2015 cash EPS. We argue BCR is an accelerating growth story with a better than average growth outlook, similar risk and near term catalysts.”

C.R. Bard closed on Thursday at $114.15.

Latest Ratings for BCR

Sep 2015JMP SecuritiesMaintainsMarket Outperform
Aug 2015Goldman SachsUpgradesNeutralBuy
Aug 2015KeyBancInitiates Coverage onSector Weight

View More Analyst Ratings for BCR
View the Latest Analyst Ratings

Posted-In: Bank of America Bob HopkinsAnalyst Color Price Target Analyst Ratings


Related Articles (BCR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters